Nimotuzumab prolongs survival in patients with malignant gliomas: A phase I/II clinical study of concomitant radiochemotherapy with or without nimotuzumab

Hong,Jidong; Peng,Yuping; Liao,Yuping; Jiang,Wuzhong; Wei,Rui; Huo,Lei; Han,Zaide; Duan,Chaojun; Zhong,Meizuo

doi:10.3892/etm.2012.555

Nimotuzumab prolongs survival in patients with malignant gliomas: A phase I/II clinical study of concomitant radiochemotherapy with or without nimotuzumab

Authors:
- Jidong Hong
- Yuping Peng
- Yuping Liao
- Wuzhong Jiang
- Rui Wei
- Lei Huo
- Zaide Han
- Chaojun Duan
- Meizuo Zhong
View Affiliations

Affiliations: Department of Oncology, The Xiangya Hospital of Central South University, Changsha 410008, P.R. China, Department of Neurosurgery, The Xiangya Hospital of Central South University, Changsha 410008, P.R. China, Department of Radiology, The Xiangya Hospital of Central South University, Changsha 410008, P.R. China, Institute of Medical Sciences, The Xiangya Hospital of Central South University, Changsha 410008, P.R. China
Published online on: April 19, 2012 https://doi.org/10.3892/etm.2012.555
Pages: 151-157

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to determine whether nimotuzumab enhances the effect of radiochemotherapy in malignant gliomas. Patients (n=41) with malignant gliomas were divided into 20 cases (treatment group) in which nimotuzumab plus radiochemotherapy were offered and 21 cases (control group) in which placebo and radiochemotherapy were administered to the patients. The response to treatment was evaluated according to the Response Evaluation Criteria in Solid Tumors, the Kaplan-Meier method was used to calculate the mean and median survival times and 1‑year survival rate, and the log-rank test and the Chi-square test were used to analyze the difference in the survival and response rate between the treatment and control groups. The mean survival times of the treatment and control groups were 14.3 and 10.4 months and the median survival times of the treatment and control groups were 16.5 and 10.5 months, respectively. The 1-year survival rates of the treatment and control groups were 81.3 and 69.1%, respectively, with no significant difference (P>0.05). The objective response rates of the treatment and control groups were 70.0 and 52.4%, respectively, with no significant difference (P>0.05). In conclusion, there was a trend towards improved treatment efficacy of radiochemotherapy combined with nimotuzumab against malignant gliomas. This study demonstrated that the use of nimotuzumab combined with radiotherapy and concomitant temozolomide chemotherapy is effective for malignant gliomas.

View Figures

View References

1	Counsell CE and Grant R: Incidence studies of primary and secondary intracranial tumors: a systematic review of their methodology and results. J Neurooncol. 37:241–250. 1998. View Article : Google Scholar : PubMed/NCBI
2	Nazzaro JM and Neuwelt EA: The role of surgery in the management of supratentorial intermediate and high-grade astrocytomas in adults. J Neurosurg. 73:331–344. 1990. View Article : Google Scholar : PubMed/NCBI
3	Wood JR, Green SB and Shapiro WR: The prognostic importance of tumor size in malignant gliomas: a computed tomographic scan study by the Brain Tumor Cooperative Group. J Clin Oncol. 6:338–343. 1988.PubMed/NCBI
4	Albert FK, Forsting M, Sartor K, Adams HP and Kunze S: Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery. 34:45–61. 1994. View Article : Google Scholar
5	Devaux BC, O’Fallon JR and Kelly PJ: Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome. J Neurosurg. 78:767–775. 1993. View Article : Google Scholar : PubMed/NCBI
6	Curran WJ Jr, Scott CB, Horton J, et al: Does extent of surgery influence outcome for astrocytoma with atypical or anaplastic foci (AAF)? A report from three Radiation Therapy Oncology Group (RTOG) trials. J Neurooncol. 12:219–227. 1992. View Article : Google Scholar : PubMed/NCBI
7	Walker MD, Alexander E Jr, Hun WE, et al: Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg. 49:333–343. 1978. View Article : Google Scholar : PubMed/NCBI
8	Walker MD, Strike TA and Sheline GE: An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys. 5:1725–1731. 1979. View Article : Google Scholar : PubMed/NCBI
9	Andersen AP: Postoperative irradiation of glioblastomas. Results in a randomized series. Acta Radiol Oncol Radiat Phys Biol. 17:475–484. 1978. View Article : Google Scholar : PubMed/NCBI
10	Kristiansen K, Hagen S, Kollevold T, et al: Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer. 47:649–652. 1981. View Article : Google Scholar
11	Laperriere N, Zuraw L and Cairncross G: Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. Radiother Oncol. 64:259–273. 2002. View Article : Google Scholar : PubMed/NCBI
12	Friedman HS, Kerby T and Calvert H: Temozolomide and treatment of malignant glioma. Clin Cancer Res. 6:2585–2597. 2000.PubMed/NCBI
13	Watkins JM, Marshall DT, Patel S, et al: High-dose radiotherapy to 78 Gy with or without temozolomide for high grade gliomas. J Neurooncol. 93:343–348. 2009. View Article : Google Scholar : PubMed/NCBI
14	Stupp R, Hegi ME, Mason WP, et al: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10:459–466. 2009.
15	Crombet T, Osorio M, Cruz T, et al: Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol. 22:1646–1654. 2004. View Article : Google Scholar : PubMed/NCBI
16	Rodriguez MO, Rivero TC, del Castillo Bahi R, et al: Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck. Cancer Biol Ther. 9:343–349. 2010. View Article : Google Scholar : PubMed/NCBI
17	World Health Organization Classification of Tumours. Pathology and genetics of tumours of the central nervous system. World Health Organization, IARC Press; Lyon: 2000
18	Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar
19	Behin A, Hoang-Xuan K, Carpentier AF and Delattre JY: Primary brain tumours in adults. Lancet. 361:323–331. 2003. View Article : Google Scholar : PubMed/NCBI
20	Macdonald DR, Cascino TL, Schold SC Jr and Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 8:1277–1280. 1990.PubMed/NCBI
21	Berg G, Blomquist E and Cavallin-Stahl E: A systematic overview of radiation therapy effects in brain tumours. Acta Oncol. 42:582–588. 2003. View Article : Google Scholar : PubMed/NCBI
22	Hegi ME, Diserens AC, Godard S, et al: Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res. 10:1871–1874. 2004. View Article : Google Scholar : PubMed/NCBI
23	Paz MF, Yaya-Tur R, Rojas-Marcos I, et al: CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res. 10:4933–4938. 2004. View Article : Google Scholar : PubMed/NCBI
24	Hegi ME, Diserens AC, Gorlia T, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 352:997–1003. 2005. View Article : Google Scholar : PubMed/NCBI
25	Diaz MA, Blanco R, Garcia B, et al: Biological activity in vitro of anti-epidermal growth factor receptor monoclonal antibodies with different affinities. Hybridoma (Larchmt). 26:423–431. 2007. View Article : Google Scholar : PubMed/NCBI
26	Ekstrand AJ, James CD, Cavenee WK, Seliger B, Pettersson RF and Collins VP: Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res. 51:2164–2172. 1991.PubMed/NCBI
27	Bredel M, Pollack IF, Hamilton RL and James CD: Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood. Clin Cancer Res. 5:1786–1792. 1999.PubMed/NCBI
28	Larysz D, Kula D, Kowal M, et al: Epidermal growth factor receptor gene expression in high grade gliomas. Folia Neuropathol. 49:28–38. 2011.PubMed/NCBI
29	Qin D, Ou G, Mo H, et al: Improved efficacy of chemotherapy for glioblastoma by radiation-induced opening of blood-brain barrier: clinical results. Int J Radiat Oncol Biol Phys. 51:959–962. 2001. View Article : Google Scholar : PubMed/NCBI
30	Van Vulpen M, Kal HB, Taphoorn MJ and El-Sharouni SY: Changes in blood-brain barrier permeability induced by radiotherapy: Implications for timing of chemotherapy? (Review). Oncol Rep. 9:683–688. 2002.PubMed/NCBI
31	Cao Y, Tsien CI, Shen Z, et al: Use of magnetic resonance imaging to assess blood-brain/blood-glioma barrier opening during conformal radiotherapy. J Clin Oncol. 23:4127–4136. 2005. View Article : Google Scholar : PubMed/NCBI
32	Ramos-Suzarte M, Rodriguez N, Oliva JP, et al: 99mTc-labeled antihuman epidermal growth factor receptor antibody in patients with tumors of epithelial origin: Part III. Clinical trials safety and diagnostic efficacy. J Nucl Med. 40:768–775. 1999.
33	Ramos TC, Figueredo J, Catala M, et al: Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial. Cancer Biol Ther. 5:375–379. 2006. View Article : Google Scholar : PubMed/NCBI
34	Giordano A, Rustum YM and Wenner CE: Cell cycle: molecular targets for diagnosis and therapy: tumor suppressor genes and cell cycle progression in cancer. J Cell Biochem. 70:1–7. 1998. View Article : Google Scholar : PubMed/NCBI
35	Petit AM, Rak J, Hung MC, et al: Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol. 151:1523–1530. 1997.
36	Kerbel RS, Viloria-Petit A, Okada F and Rak J: Establishing a link between oncogenes and tumor angiogenesis. Mol Med. 4:286–295. 1998.PubMed/NCBI
37	Gibson S, Tu S, Oyer R, Anderson SM and Johnson GL: Epidermal growth factor protects epithelial cells against Fas-induced apoptosis. Requirement for Akt activation. J Biol Chem. 274:17612–17618. 1999. View Article : Google Scholar : PubMed/NCBI
38	Lammering G, Hewit TH, Hawkins WT, et al: Epidermal growth factor receptor as a genetic therapy target for carcinoma cell radiosensitization. J Natl Cancer Inst. 93:921–929. 2001. View Article : Google Scholar : PubMed/NCBI
39	Lammering G: Anti-epidermal growth factor receptor strategies to enhance radiation action. Curr Med Chem Anticancer Agents. 3:327–333. 2003. View Article : Google Scholar : PubMed/NCBI
40	Damiano V, Melisi D, Bianco C, et al: Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma. Clin Cancer Res. 11:5639–5644. 2005. View Article : Google Scholar : PubMed/NCBI
41	Diaz MA, Rolff J, Lemm M, Fichtner I, Perez R and Montero E: Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies. Br J Cancer. 100:950–958. 2009. View Article : Google Scholar : PubMed/NCBI
42	Gorski DH, Beckett MA, Jaskowiak NT, et al: Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 59:3374–3378. 1999.PubMed/NCBI
43	Perrotte P, Matsumoto T, Inoue K, et al: Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res. 5:257–265. 1999.PubMed/NCBI
44	Coleman CN and Stevenson MA: Biologic basis for radiation oncology. Oncology (Williston Park). 10:399–415. 1996.
45	Bandyopadhyay D, Mandal M, Adam L, Mendelsohn J and Kumar R: Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells. J Biol Chem. 273:1568–1573. 1998. View Article : Google Scholar : PubMed/NCBI
46	Kwok TT and Sutherland RM: Cell cycle dependence of epidermal growth factor induced radiosensitization. Int J Radiat Oncol Biol Phys. 22:525–527. 1992. View Article : Google Scholar : PubMed/NCBI
47	Laderoute KR, Ausserer WA, Knapp AM, Grant TD and Sutherland RM: Epidermal growth factor modifies cell cycle control in A431 human squamous carcinoma cells damaged by ionizing radiation. Cancer Res. 54:1407–1411. 1994.PubMed/NCBI
48	Huang SM and Harari PM: Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res. 6:2166–2174. 2000.